spesolimab

Modality

mAb

Mechanism

12.1 Mechanism of Action Spesolimab-sbzo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 (IL-36) signaling by specifically binding to the IL36R. Binding of spesolimab-sbzo to IL36R prevents the subsequent activation of IL36R by its ligands (IL-36 α, β and γ) and downstream activation of pro-inflammatory and pro-fibrotic pathways. The precise mechanism linking reduced IL36R activity and the treatment of flares of GPP is unclear.

Targets

IL-36R

Storage

—

Approved

psoriasis — FDA

In trial

psoriasis, atopic dermatitis, hidradenitis suppurativa

Sources

DailyMed (FDA label)DrugBank ClinicalTrials.gov

Last verified

2026-04-23

No curated MOA diagram yet. See lib/moa-data.ts for the shape; add an entry keyed by spesolimab.

Monitoring & workup

Baseline workup

•TB IGRA (or PPD)
•HBV sAg if high risk; HCV Ab if high risk
•Update age-appropriate vaccines before start

Ongoing monitoring

•No routine labs
•Annual TB screening if high exposure risk
•IL-17 class: monitor for candida overgrowth + IBD flare
•IL-23 class: monitor for injection-site reactions